Skip to content

Nicolas Tournier

5 papers in the library · 137 citations · publishing 2009-2025

Papers

Sort Most recent Most cited

Quantitative monitoring of ketamine's impact on synaptic density using 11C-UCB-J PET imaging in the corticosterone mouse model of anxiety/depression.

Molecular Psychiatry November 18, 2025 Cassandre Corvo, Sébastien Goutal, Indira Mendez-David et al. 1 citation

Ketamine was shown to promote synaptogenesis, which is thought to account for its antidepressant effects through the restoration of lost synaptic connections observed in depression. PET imaging using 11C-UCB-J, a radiotracer targeting the synaptic vesicle protein 2 A (SV2A), was investigated as a translational method to monitor ketamine-induced changes in synaptic density in the corticosterone...

DOI: 10.1038/s41380-025-03369-3 (opens in new tab) Full text (opens in new tab) Ketamine ketamine Single ketamine dose Repeated doses Neuroplasticity brain connections +14

Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in Humans.

Clinical Pharmacokinetics November 1, 2025 Léa Comin, Solène Marie, Moreno Ursino et al.

Whole-body dynamic (WB4D) positron emission tomography (PET) imaging data using radiolabeled analogs of drugs are mostly analyzed using descriptive approaches, with no relationship to traditional pharmacokinetic studies based on blood sampling. Here, we build a pharmacokinetic (PK) model from WB4D PET data obtained using a microdose of radiolabeled glyburide ([11C]glyburide) in humans, aiming...

Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

The International Journal of Neuropsychopharmacology August 1, 2010 Nicolas Tournier, Lucie Chevillard, Bruno Mégarbane et al. 122 citations

Drug interaction with P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) may influence its tissue disposition including blood-brain barrier transport and result in potent drug-drug interactions. The limited data obtained using in-vitro models indicate that methadone, buprenorphine, and cannabinoids may interact with human P-gp; but almost nothing is known about drugs of abuse and...

Ibogaine labeling with 99mTc-tricarbonyl: synthesis and transport at the mouse blood-brain barrier.

Journal of Pharmaceutical Sciences December 1, 2009 Nicolas Tournier, Pascal André, Sandy Blondeel et al. 14 citations

The (99m)Tc-tricarbonyl core may be used as an ideal tool for gamma-labeling ligands in noninvasive SPECT imaging. However, most (99m)Tc-tricarbonyl-labeled agents have difficulty crossing the blood-brain barrier (BBB). We radiolabeled the neuroactive indole ibogaine with (99m)Tc-tricarbonyl and measured its transport into the mouse brain by in situ brain perfusion. We measured the interactions...

DOI: 10.1002/jps.21771 (opens in new tab) Full text (opens in new tab) Brain imaging Neuroimaging Molecular imaging Imaging agents +23

A novel workflow integrating whole-body PET microdosing data and therapeutic-dose pharmacokinetics across species to inform first-in-human dose selection

Bach Tran Nguyen, Aurélie Barrail-Tran, Moreno Ursino et al.

Introduction: First-in-human studies require dose extrapolation from pharmacokinetic animal studies combined with safety assessments. Subtherapeutic doses of radiolabelled drugs can be administered in preclinical and early clinical development to gain a dynamic pharmacokinetic understanding, potentially informing pharmacologically-based pharmacokinetics (PBPK) models through whole-body PET...